Show simple item record

dc.contributor.authorJarfelt, Marianne
dc.contributor.authorAndersen, Niels H
dc.contributor.authorGlosli, Heidi
dc.contributor.authorJahnukainen, Kirsi
dc.contributor.authorJónmundsson, Guðmundur K
dc.contributor.authorMalmros, Johan
dc.contributor.authorNysom, Karsten
dc.contributor.authorHasle, Henrik
dc.date.accessioned2016-08-03T15:33:00Z
dc.date.available2016-08-03T15:33:00Z
dc.date.issued2016-07
dc.date.submitted2016
dc.identifier.citationCardiac function in survivors of childhood acute myeloid leukemia treated with chemotherapy only: a NOPHO-AML study. 2016, 97 (1):55-62 Eur. J. Haematol.en
dc.identifier.issn1600-0609
dc.identifier.pmid26383901
dc.identifier.doi10.1111/ejh.12683
dc.identifier.urihttp://hdl.handle.net/2336/617901
dc.descriptionTo access publisher's full text version of this article click on the hyperlink at the bottom of the pageen
dc.description.abstractWe report cardiac function of patients treated for Childhood acute myeloid leukemia with chemotherapy only according to three consecutive Nordic protocols.
dc.description.abstractNinety-eight of 138 eligible patients accepted examination with standardized echocardiography. Results were compared with age- and sex-matched controls.
dc.description.abstractThe median age was 3 yr at diagnosis (range 0-15), and the median time from diagnosis to study was 11 yr (4-25). All but one patient had received doxorubicin and 90% had received mitoxantrone. The median cumulative dose of daunorubicin equivalents was 300 mg/m(2) (210-525). Left ventricular fractional shortening (LVFS) and ejection fraction (LVEF) were lower in patients than in controls (32.6% (SD 4.0) vs. 35.2% (SD 3.4), P = 0.002 and 59.9% (SD 5.5) vs. 64.2% (SD 4.4), P = 0.001). The myocardial performance index (MPI) was higher in patients than in controls (0.32 (SD 0.081) vs. 0.26 (SD 0.074), P < 0.0001). Cumulative dose of doxorubicin but not mitoxantrone was related to lower LVFS (P = 0.037) and LVEF (P = 0.016). Longer follow-up was associated with lower LVFS (P = 0.034). Higher MPI was associated with young age at diagnosis (P = 0.04) and longer follow-up (P = 0.031).
dc.description.abstractIn this study, most patients had cardiac function within normal limits and reported very few cardiac symptoms. However, compared with healthy controls, they had significantly reduced left ventricular function.
dc.description.sponsorshipDanish Cancer Society Danish Childhood Cancer Foundation Karen Elise Jensen Foundation Swedish Childhood Cancer Foundationen
dc.language.isoenen
dc.publisherWiley-Blackwellen
dc.relation.urlhttp://dx.doi.org/ 10.1111/ejh.12683en
dc.relation.urlhttp://onlinelibrary.wiley.com/doi/10.1111/ejh.12683/epdfen
dc.rightsArchived with thanks to European journal of haematologyen
dc.subjectHvítblæðien
dc.subjectBörnen
dc.subjectLyfjameðferðen
dc.subjectHjartasjúkdómaren
dc.subjectPED12
dc.subject.meshLeukemia, Myeloid, Acuteen
dc.subject.meshCardiotoxicityen
dc.subject.meshChilden
dc.subject.meshDrug Therapy/adverse effectsen
dc.titleCardiac function in survivors of childhood acute myeloid leukemia treated with chemotherapy only: a NOPHO-AML study.en
dc.typeArticleen
dc.contributor.department[ 1 ] Sahlgrens Univ Hosp, Dept Pediat, S-41685 Gothenburg, Sweden [ 2 ] Aarhus Univ Hosp Skejby, Dept Internal Med, Aarhus, Denmark [ 3 ] Univ Oslo, Rikshosp, Univ Hosp Oslo, Dept Pediat, N-0027 Oslo, Norway [ 4 ] Univ Helsinki, Childrens Hosp, Helsinki, Finland [ 5 ] Landspitalinn Univ Hosp, Dept Pediat, Reykjavik, Iceland   Organization-Enhanced Name(s)      Landspitali National University Hospital [ 6 ] Karolinska Univ Hosp, Dept Pediat Oncol, Stockholm, Sweden [ 7 ] Rigshosp, Pediat & Adolescent Med, Univ Hosp, DK-2100 Copenhagen, Denmark [ 8 ] Aarhus Univ Hosp Skejby, Dept Pediat, Aarhus, Denmarken
dc.identifier.journalEuropean journal of haematologyen
dc.rights.accessLandspitali Access - LSH-aðganguren
html.description.abstractWe report cardiac function of patients treated for Childhood acute myeloid leukemia with chemotherapy only according to three consecutive Nordic protocols.
html.description.abstractNinety-eight of 138 eligible patients accepted examination with standardized echocardiography. Results were compared with age- and sex-matched controls.
html.description.abstractThe median age was 3 yr at diagnosis (range 0-15), and the median time from diagnosis to study was 11 yr (4-25). All but one patient had received doxorubicin and 90% had received mitoxantrone. The median cumulative dose of daunorubicin equivalents was 300 mg/m(2) (210-525). Left ventricular fractional shortening (LVFS) and ejection fraction (LVEF) were lower in patients than in controls (32.6% (SD 4.0) vs. 35.2% (SD 3.4), P = 0.002 and 59.9% (SD 5.5) vs. 64.2% (SD 4.4), P = 0.001). The myocardial performance index (MPI) was higher in patients than in controls (0.32 (SD 0.081) vs. 0.26 (SD 0.074), P < 0.0001). Cumulative dose of doxorubicin but not mitoxantrone was related to lower LVFS (P = 0.037) and LVEF (P = 0.016). Longer follow-up was associated with lower LVFS (P = 0.034). Higher MPI was associated with young age at diagnosis (P = 0.04) and longer follow-up (P = 0.031).
html.description.abstractIn this study, most patients had cardiac function within normal limits and reported very few cardiac symptoms. However, compared with healthy controls, they had significantly reduced left ventricular function.


This item appears in the following Collection(s)

Show simple item record